Emergent BioSolutions Inc. (NYSE: EBS) Stock Competitors & Peer Comparison

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TAK has a market cap of 63.9B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TAK trades at $20.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TAK's P/E ratio is 14.44. In terms of profitability, EBS's ROE is -0.36%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TAK's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TEVA has a market cap of 47.6B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TEVA trades at $40.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TEVA's P/E ratio is 13.95. In terms of profitability, EBS's ROE is -0.36%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TEVA's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, HLN has a market cap of 44.7B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while HLN trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas HLN's P/E ratio is 20.82. In terms of profitability, EBS's ROE is -0.36%, compared to HLN's ROE of +0.10%. Regarding short-term risk, EBS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HLN's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ZTS has a market cap of 33.1B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ZTS trades at $80.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ZTS's P/E ratio is 12.17. In terms of profitability, EBS's ROE is -0.36%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, EBS is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ZTS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while VTRS trades at $18.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas VTRS's P/E ratio is 7.40. In terms of profitability, EBS's ROE is -0.36%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EBS is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check VTRS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EBS's ROE is -0.36%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EBS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ITCI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EBS's ROE is -0.36%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EBS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CTLT's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ELAN has a market cap of 11.3B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ELAN trades at $22.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ELAN's P/E ratio is 21.42. In terms of profitability, EBS's ROE is -0.36%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EBS is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ELAN's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, RDY has a market cap of 11B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while RDY trades at $13.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas RDY's P/E ratio is 28.23. In terms of profitability, EBS's ROE is -0.36%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RDY's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ALKS trades at $44.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ALKS's P/E ratio is 46.43. In terms of profitability, EBS's ROE is -0.36%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, EBS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALKS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while LNTH trades at $100.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas LNTH's P/E ratio is 16.87. In terms of profitability, EBS's ROE is -0.36%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EBS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LNTH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AMRX has a market cap of 6.3B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AMRX trades at $19.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AMRX's P/E ratio is 22.04. In terms of profitability, EBS's ROE is -0.36%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EBS is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AMRX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, RGC has a market cap of 5.2B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while RGC trades at $10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas RGC's P/E ratio is -1045.00. In terms of profitability, EBS's ROE is -0.36%, compared to RGC's ROE of -1.61%. Regarding short-term risk, EBS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check RGC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while INDV trades at $34.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas INDV's P/E ratio is 9.53. In terms of profitability, EBS's ROE is -0.36%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EBS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for EBS.Check INDV's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while HCM trades at $14.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas HCM's P/E ratio is 142.55. In terms of profitability, EBS's ROE is -0.36%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HCM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ALVOW trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, EBS's ROE is -0.36%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, EBS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALVOW's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SUPN trades at $41.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SUPN's P/E ratio is 13.47. In terms of profitability, EBS's ROE is -0.36%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EBS is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SUPN's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while BHC trades at $6.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas BHC's P/E ratio is 1.64. In terms of profitability, EBS's ROE is -0.36%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EBS is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BHC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PRGO trades at $16.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PRGO's P/E ratio is 6.47. In terms of profitability, EBS's ROE is -0.36%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PRGO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EBS's ROE is -0.36%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DCPH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EBS's ROE is -0.36%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, EBS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AVDL's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EBS's ROE is -0.36%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EBS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check EMBCV's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TRLV has a market cap of 1.8B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TRLV trades at $10.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TRLV's P/E ratio is -4.38. In terms of profitability, EBS's ROE is -0.36%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, EBS is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TRLV's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ALVO trades at $5.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ALVO's P/E ratio is -8.68. In terms of profitability, EBS's ROE is -0.36%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, EBS is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ALVO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EBS's ROE is -0.36%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DVAX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ANIP trades at $72.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ANIP's P/E ratio is 8.84. In terms of profitability, EBS's ROE is -0.36%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EBS is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ANIP's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TARO's P/E ratio is 30.05. In terms of profitability, EBS's ROE is -0.36%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EBS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TARO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PAHC trades at $38.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PAHC's P/E ratio is 13.24. In terms of profitability, EBS's ROE is -0.36%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EBS is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PAHC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PCRX trades at $36.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PCRX's P/E ratio is 13.99. In terms of profitability, EBS's ROE is -0.36%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PCRX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ETON trades at $50.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ETON's P/E ratio is 132.08. In terms of profitability, EBS's ROE is -0.36%, compared to ETON's ROE of +0.40%. Regarding short-term risk, EBS is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ETON's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CRON trades at $3.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CRON's P/E ratio is 16.79. In terms of profitability, EBS's ROE is -0.36%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EBS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CRON's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AMPH trades at $25.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AMPH's P/E ratio is 8.85. In terms of profitability, EBS's ROE is -0.36%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EBS is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AMPH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while HROW trades at $28.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas HROW's P/E ratio is -28.35. In terms of profitability, EBS's ROE is -0.36%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EBS is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for EBS.Check HROW's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EBS's ROE is -0.36%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PETQ's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, COLL has a market cap of 756.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while COLL trades at $23.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas COLL's P/E ratio is 2.91. In terms of profitability, EBS's ROE is -0.36%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EBS is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check COLL's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, IRWD has a market cap of 599.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while IRWD trades at $3.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas IRWD's P/E ratio is 4.65. In terms of profitability, EBS's ROE is -0.36%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EBS is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for EBS.Check IRWD's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EBS's ROE is -0.36%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EBS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BDSI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, EVO has a market cap of 525.7M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while EVO trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas EVO's P/E ratio is -2.09. In terms of profitability, EBS's ROE is -0.36%, compared to EVO's ROE of -0.27%. Regarding short-term risk, EBS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AQST has a market cap of 508.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AQST trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AQST's P/E ratio is -6.23. In terms of profitability, EBS's ROE is -0.36%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EBS is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AQST's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, EOLS has a market cap of 486.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while EOLS trades at $7.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas EOLS's P/E ratio is -23.34. In terms of profitability, EBS's ROE is -0.36%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EBS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EOLS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, KMDA has a market cap of 452.9M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while KMDA trades at $7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas KMDA's P/E ratio is 20.66. In terms of profitability, EBS's ROE is -0.36%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EBS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check KMDA's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TKNO has a market cap of 396.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TKNO trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TKNO's P/E ratio is -23.84. In terms of profitability, EBS's ROE is -0.36%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EBS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TKNO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TLRY trades at $3.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TLRY's P/E ratio is -2.16. In terms of profitability, EBS's ROE is -0.36%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, EBS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TLRY's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CGC has a market cap of 304.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CGC trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CGC's P/E ratio is -1.61. In terms of profitability, EBS's ROE is -0.36%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EBS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CGC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EBS's ROE is -0.36%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EBS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALIM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EBS's ROE is -0.36%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EBS is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LNDC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ACB trades at $3.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ACB's P/E ratio is -2.87. In terms of profitability, EBS's ROE is -0.36%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EBS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ACB's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, LFCR has a market cap of 241.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while LFCR trades at $6.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas LFCR's P/E ratio is -5.02. In terms of profitability, EBS's ROE is -0.36%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, EBS is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LFCR's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EBS's ROE is -0.36%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EBS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TYHT's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SIGA has a market cap of 226.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SIGA trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SIGA's P/E ratio is 11.67. In terms of profitability, EBS's ROE is -0.36%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EBS is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SIGA's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, GLAS has a market cap of 182M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while GLAS trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas GLAS's P/E ratio is -4.15. In terms of profitability, EBS's ROE is -0.36%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, EBS is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GLAS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas REPH's P/E ratio is -8.04. In terms of profitability, EBS's ROE is -0.36%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EBS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check REPH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas THTX's P/E ratio is -28.83. In terms of profitability, EBS's ROE is -0.36%, compared to THTX's ROE of +0.36%. Regarding short-term risk, EBS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check THTX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EBS's ROE is -0.36%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EBS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ASRT's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, DERM has a market cap of 147.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while DERM trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas DERM's P/E ratio is -23.73. In terms of profitability, EBS's ROE is -0.36%, compared to DERM's ROE of -0.20%. Regarding short-term risk, EBS is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check DERM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CRDL has a market cap of 138.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CRDL trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CRDL's P/E ratio is -4.58. In terms of profitability, EBS's ROE is -0.36%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, EBS is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CRDL's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, OGI has a market cap of 132.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while OGI trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas OGI's P/E ratio is 2.10. In terms of profitability, EBS's ROE is -0.36%, compared to OGI's ROE of +0.21%. Regarding short-term risk, EBS is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OGI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ORGO trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ORGO's P/E ratio is 34.00. In terms of profitability, EBS's ROE is -0.36%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EBS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ORGO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CPIX trades at $7.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CPIX's P/E ratio is -19.90. In terms of profitability, EBS's ROE is -0.36%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EBS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CPIX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EBS's ROE is -0.36%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EBS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SCTL's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, BGM has a market cap of 108.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while BGM trades at $8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas BGM's P/E ratio is -1.78. In terms of profitability, EBS's ROE is -0.36%, compared to BGM's ROE of -0.05%. Regarding short-term risk, EBS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check BGM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PROC's P/E ratio is 1.53. In terms of profitability, EBS's ROE is -0.36%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EBS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PROC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EBS's ROE is -0.36%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EBS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OPTN's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EBS's ROE is -0.36%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EBS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZOM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EBS's ROE is -0.36%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, EBS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GRVI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ZYBT trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, EBS's ROE is -0.36%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, EBS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZYBT's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EBS's ROE is -0.36%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EBS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZYNE's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EBS's ROE is -0.36%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EBS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SSIC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EBS's ROE is -0.36%, compared to VLNS's ROE of N/A. Regarding short-term risk, EBS is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check VLNS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EBS's ROE is -0.36%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, EBS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DRRX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TLPH has a market cap of 55.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TLPH trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TLPH's P/E ratio is -3.96. In terms of profitability, EBS's ROE is -0.36%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, EBS is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TLPH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, INCR has a market cap of 53.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while INCR trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas INCR's P/E ratio is -4.76. In terms of profitability, EBS's ROE is -0.36%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EBS is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for EBS.Check INCR's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EBS's ROE is -0.36%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, EBS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EBS.Check JUPW's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas QLI's P/E ratio is -4.92. In terms of profitability, EBS's ROE is -0.36%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EBS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check QLI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EBS's ROE is -0.36%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EBS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check HEXO's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CPHI has a market cap of 31.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CPHI trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CPHI's P/E ratio is -1.68. In terms of profitability, EBS's ROE is -0.36%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, EBS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CPHI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, RMTI has a market cap of 29.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while RMTI trades at $7.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas RMTI's P/E ratio is -5.40. In terms of profitability, EBS's ROE is -0.36%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, EBS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RMTI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EBS's ROE is -0.36%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EBS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CYTH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SHPH has a market cap of 23.4M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SHPH trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SHPH's P/E ratio is -0.23. In terms of profitability, EBS's ROE is -0.36%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, EBS is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SHPH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, TXMD has a market cap of 22.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while TXMD trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas TXMD's P/E ratio is 97.30. In terms of profitability, EBS's ROE is -0.36%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EBS is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TXMD's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AYTU has a market cap of 21.8M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AYTU trades at $2.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AYTU's P/E ratio is -1.70. In terms of profitability, EBS's ROE is -0.36%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, EBS is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AYTU's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, OPTH has a market cap of 19.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while OPTH trades at $3.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas OPTH's P/E ratio is -2.15. In terms of profitability, EBS's ROE is -0.36%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, EBS is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check OPTH's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EBS's ROE is -0.36%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, EBS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVOK's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EBS's ROE is -0.36%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, EBS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ACRX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EBS's ROE is -0.36%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EBS is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AGRX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, CABR has a market cap of 9.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while CABR trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas CABR's P/E ratio is -1.36. In terms of profitability, EBS's ROE is -0.36%, compared to CABR's ROE of -3.86%. Regarding short-term risk, EBS is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CABR's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EBS's ROE is -0.36%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EBS is similarly volatile compared to NLTX. This indicates similar risk in terms of short-term price fluctuations for EBS.Check NLTX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas LCI's P/E ratio is -0.04. In terms of profitability, EBS's ROE is -0.36%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EBS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check LCI's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, INM has a market cap of 7.4M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while INM trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas INM's P/E ratio is -0.44. In terms of profitability, EBS's ROE is -0.36%, compared to INM's ROE of -1.35%. Regarding short-term risk, EBS is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check INM's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EBS's ROE is -0.36%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EBS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ADMP's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, SNOA has a market cap of 5.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while SNOA trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas SNOA's P/E ratio is -1.05. In terms of profitability, EBS's ROE is -0.36%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EBS is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SNOA's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas MNK's P/E ratio is -0.44. In terms of profitability, EBS's ROE is -0.36%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EBS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EBS.Check MNK's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, YCBD has a market cap of 4.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while YCBD trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas YCBD's P/E ratio is -0.95. In terms of profitability, EBS's ROE is -0.36%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EBS is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for EBS.Check YCBD's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EBS's ROE is -0.36%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EBS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check FLGC's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, GELS has a market cap of 4.1M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while GELS trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas GELS's P/E ratio is -1.02. In terms of profitability, EBS's ROE is -0.36%, compared to GELS's ROE of -0.36%. Regarding short-term risk, EBS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GELS's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, AKAN has a market cap of 2.6M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while AKAN trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas AKAN's P/E ratio is -0.02. In terms of profitability, EBS's ROE is -0.36%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, EBS is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AKAN's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EBS's ROE is -0.36%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EBS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check PLXP's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EBS's ROE is -0.36%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EBS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ATNX's competition here

Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EBS stands at 322.5M. In comparison, UPC has a market cap of 2.2M. Regarding current trading prices, EBS is priced at $6.29 on the NYSE, while UPC trades at $3.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EBS currently has a P/E ratio of 4.37, whereas UPC's P/E ratio is -0.44. In terms of profitability, EBS's ROE is -0.36%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EBS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check UPC's competition here